Minimal Contrast Dye Product Development

Restricted access

Two companies with products that reduce the amount of contrast dye in a patient’s system are raising money to increase sales and to support critical research. Contrast dye used in vascular and other imaging may cause such complications as acute kidney injury (AKI) in kidney-impaired patients.

Osprey Medical’s (Minnetonka, MN) DyeVert PLUS, which received FDA marketing clearance in March 2017, allows for a minimization of contrast dose, contrast monitoring in real-time, and notification to physicians when limits based on kidney function are reached. A special syringe allows release of minimal dye needed, with recapture of the unused portion.

Osprey plans

Save